Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: A proof of concept and feasibility study

Gynecologic and Obstetric Investigation

Volumn 76, Issue 2, 2013, Pages 113-118

  Weissman, Ariel ^a,b   Ravhon, Amir ^a,b   Steinfeld, Zohar ^a,b   Nahum, Hana ^a,b   Golan, Abraham ^a,b   Levran, David ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Assisted reproductive technologies; Controlled ovarian stimulation; GnRH antagonist; Long protocol

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED OVARIAN STIMULATION; CONTROLLED STUDY; DISEASE DURATION; ECTOPIC PREGNANCY; EMBRYO TRANSFER; ENDOMETRIAL THICKNESS; ESTRADIOL BLOOD LEVEL; FEASIBILITY STUDY; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MENSTRUATION; OOCYTE RETRIEVAL; OVARY FOLLICLE; PARITY; PREGNANCY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; OVULATION INDUCTION;

ADULT; DINOPROSTONE; FEASIBILITY STUDIES; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; MENOTROPINS; OOCYTE RETRIEVAL; OVARIAN FOLLICLE; OVULATION INDUCTION; PREGNANCY; PROGESTERONE; SPERM INJECTIONS, INTRACYTOPLASMIC; TIME FACTORS;

EID: 84884202435     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000351570     Document Type: Article

References (30)

1. Al-Inany H, Aboulghar M: Gonadotrophinreleasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2001;4:CD001750.
2. Al-Inany HG, Abou-Setta AM, Aboulghar M: Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; 3:CD001750.
3. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G: Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006; 12: 651-671.
4. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou- Setta AM: Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;11:CD001750.
5. Borm G, Mannaerts B: Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000; 15: 1490-1498.
6. Fleming R: Monitoring during gonadotrophin- releasing hormone antagonist protocols. Reprod Biomed Online 2010;21:446-449.
7. Kolibianakis EM, Zikopoulos K, Smitz J, Camus M, Tournaye H, Van Steirteghem AC, Devroey P: Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod 2004; 19: 1525-1529.
8. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, Devroey P: Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003; 79: 873-880.
9. Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P: Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pickup. Fertil Steril 2002; 78: 1025-1029.
10. Weissman A, Farhi J, Royburt M, Nahum H, Glezerman M, Levran D: Prospective evaluation of two stimulation protocols for low responders who were undergoing in vitro fertilization- embryo transfer. Fertil Steril 2003; 79: 886-892.
11. Albano C, Felberbaum RE, Smitz J, Riethmuller- Winzen H, Engel J, Diedrich K, Devroey P: Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin: European Cetrorelix Study Group. Hum Reprod 2000; 15: 526-531.
12. Group EaMEOS: Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644-651.
13. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, Shapiro DB: Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75: 38-45.
14. Fleming R, Jenkins J: The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reprod Biomed Online 2010; 21: 446-449.
15. Weissman A, Ravhon A, Biran G, Levin D, Golan A, Levran D: Follicular growth and development under continuous gonadotropinreleasing hormone antagonist administration. Fertil Steril 2007; 88: 1677.e1615-1677.
16. Hernandez ER: Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000; 15: 1211-1216.
17. The Ganirelix Dose-Finding Study Group: A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin- releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998; 13: 3023-3031.
18. Fanchin R, Mendez Lozano DH, Schonauer LM, Cunha-Filho JS, Frydman R: Hormonal manipulations in the luteal phase to coordinate subsequent antral follicle growth during ovarian stimulation. Reprod Biomed Online 2005; 10: 721-728.
19. Dragisic KG, Davis OK, Fasouliotis SJ, Rosenwaks Z: Use of a luteal estradiol patch and a gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation for in vitro fertilization in poor responders. Fertil Steril 2005; 84: 1023-1026.
20. Fisch JD, Keskintepe L, Sher G: Gonadotropin- releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure. Fertil Steril 2008; 89: 342-347.
21. Frattarelli JL, Hill MJ, McWilliams GD, Miller KA, Bergh PA, Scott RT Jr: A luteal estradiol protocol for expected poor-responders improves embryo number and quality. Fertil Steril 2007; 89: 1118-1122.
22. Weitzman VN, Engmann L, DiLuigi A, Maier D, Nulsen J, Benadiva C: Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes. Fertil Steril 2009; 92: 226-230.
23. Cedrin-Durnerin I, Guivarc'h-Leveque A, Hugues JN: Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril 2012; 97: 1359-1364.e1.
24. Cedrin-Durnerin I, Bstandig B, Parneix I, Bied-Damon V, Avril C, Decanter C, Hugues JN: Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before gnrh antagonist protocol. Hum Reprod 2007; 22: 109-116.
25. Rombauts L, Healy D, Norman RJ: A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod 2006; 21: 95-103.
26. Huirne JA, Hugues JN, Pirard C, Fischl F, Sage JC, Pouly JL, Obruca A, Braat DM, van Loenen AC, Lambalk CB: Cetrorelix in an oral contraceptive- pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Hum Reprod 2006; 21: 1408-1415.
27. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P: Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 2003; 88: 5632-5637.
28. Lainas TG, Petsas GK, Zorzovilis IZ, Iliadis GS, Lainas GT, Cazlaris HE, Kolibianakis EM: Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod 2007; 22: 1540-1546.
29. Blockeel C, Riva A, De Vos M, Haentjens P, Devroey P: Administration of a gonadotropin- releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/ intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation: a pilot study. Fertil Steril 2011; 95: 1714-1719.e2.
30. Younis JS, Soltsman S, Izhaki I, Radin O, Bar- Ami S, Ben-Ami M: Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization-embryo transfer cycles. Fertil Steril 2010; 94: 1350-1355.